Tag: Sickle-Cell Anemia
Transcranial Doppler, Hydroxyurea Use Low for Sickle Cell Anemia
Despite increases in TCD screening and hydroxyurea use from 2014 to 2019, use still remains low for children, teens
Burden of Medical Costs for Sickle Cell Disease Quantified
Over nonelderly lifetime, SCD-attributable costs were estimated at $1.7 million for males; with out-of-pocket costs of $45,091
Systemic Corticosteroids Tied to Vaso-Occlusive Episodes in Sickle Cell
Association seen among children and adults with sickle cell disease; association lower for those exposed to hydroxyurea
Male Teens With Sickle Cell Disease Unaware of Related Fertility Issues
Authors say educational materials and fertility testing options are needed
Risk of Stillbirth Up for Pregnant People With Sickle Cell Trait
In fully adjusted model, increased risk of stillbirth also seen for those with sickle cell disease, multiple gestations
ASH Issues Guideline on the Use of HSCT for Sickle Cell Disease
The use of HSCT for sickle cell disease is evolving, and no randomized controlled trials were identified in the evidence review for this guideline
Sickle Cell Disease May Up Risk for Poor COVID-19 Outcomes
Sickle cell trait also associated with increased risk for COVID-19-related hospitalization and death, but to a lesser extent
Risk Factors ID’d for Severe COVID-19 With Sickle Cell Disease
Hydroxyurea use does not impact development of serious COVID-19 or need for hospitalization in children or adults
Treatment at Infusion Center Beneficial in Sickle Cell Disease
Outcomes significantly better for treatment of vaso-occlusive crises at infusion center versus emergency department
Gene Therapy for Sickle Cell Did Not Cause Patient’s Leukemia
Bluebird Bio says it has not found evidence that its gene therapy caused the sickle cell patient's leukemia
